Atyr PHARMA (NASDAQ:ATYR – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01, Yahoo Finance reports.
Atyr PHARMA Stock Performance
Shares of NASDAQ ATYR traded up $0.15 during mid-day trading on Thursday, reaching $2.00. 709,013 shares of the company were exchanged, compared to its average volume of 480,650. Atyr PHARMA has a 52 week low of $1.08 and a 52 week high of $2.50. The company has a market capitalization of $138.02 million, a P/E ratio of -2.06 and a beta of 1.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.07.
Insiders Place Their Bets
In other news, Director Paul Schimmel bought 52,300 shares of the business’s stock in a transaction on Wednesday, July 24th. The stock was acquired at an average price of $1.93 per share, with a total value of $100,939.00. Following the completion of the purchase, the director now directly owns 413,023 shares in the company, valued at $797,134.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.70% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Report on Atyr PHARMA
About Atyr PHARMA
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Recommended Stories
- Five stocks we like better than Atyr PHARMA
- Insider Trading – What You Need to Know
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- What is a Stock Market Index and How Do You Use Them?
- Jeff Brown’s Exegesis AI Stock Picks
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.